Dawson James Reiterates Buy Rating on Sorrento Therapeutics (SRNE) on FDA Clearance for Phase 2 of Abivertinib in COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CME
10. INTC

Go back to Dawson James Reiterates Buy Rating on Sorrento Therapeutics (SRNE) on FDA Clearance for Phase 2 of Abivertinib in COVID-19

Sorrento Therapeutics (SRNE) CEO on Mad Money tonight

July 20, 2020 10:00 AM EDT

Sorrento Therapeutics (NASDAQ: SRNE) CEO on Mad Money tonight

... More

Sorrento Therapeutics (SRNE) Granted FDA Okay for Phase 2 Study of Abivertinib in COVID-19

July 20, 2020 9:03 AM EDT

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) received clearance from the FDA to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms.

Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA... More